Price movement over the last 24 hours
ARK Next Generation Internet ETF vs Mesoblast Limited — how do they compare? ARK Next Generation Internet ETF trades at $147, while Mesoblast Limited trades at $16.01 (market cap $2.00B). Which is the better fit depends on your goals.
| ARKW | MESO | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $182.20 | $20.96 |
52-Week Low | $114.45 | $10.96 |
Market Cap | — | $2.00B |
Enterprise Value | — | $2.00B |
Signals from Pluang's Aura AI — not financial advice
ARKW trades at $148.42, down 0.75% with a bullish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 52.51 suggesting balanced buying pressure. Support levels are established at $144 and $142, while resistance sits at $147 and $148. Recent news highlights Cathie Wood's continued focus on innovative technology investments through her ETF strategies.
The ETF's exposure to disruptive innovation themes presents growth potential amid technology sector momentum. Key risks include concentration in high-growth tech stocks and market volatility sensitivity. Institutional interest remains strong given ARK Invest's track record in identifying transformative technologies.
MESO trades at $15.44, up 4.11% today, with a bullish technical signal from moving averages but overbought RSI near 89. The company reported a net loss of $102.14 million in 2025 despite an 80.52% gross margin, while recent news highlights Ryoncil revenue growth and FDA progress for its heart failure treatment, signaling a transition to commercial operations.
The outlook is cautiously optimistic, driven by product commercialization and pipeline advancements, but high cash burn and negative margins pose significant risks. Analyst consensus leans buy (45% of ratings), yet the stock's elevated P/S ratio of 30.52 demands careful valuation assessment amid ongoing losses.
Trailing returns across standard periods
Latest headlines on both assets
ARKW is an actively managed ETF that invests in next-generation internet technologies. It focuses on cloud computing, AI, e-commerce, and blockchain innovation, with key holdings like Tesla, Advanced Micro Devices, and Roku.
Read more on ARKW →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →